CONCORD HC GP (02453) announced that its subsidiary, Guangzhou Concord Cancer Hospital, has been approved by the Guangdong Provincial Health Commission and the Guangdong Provincial Medical Products Administration on December 8, 2025, for inclusion in the "Greater Bay Area Drug and Device Access" designated medical institutions list.

The "Greater Bay Area Drug and Device Access" initiative is a core implementation measure under the "Greater Bay Area Pharmaceutical and Medical Device Regulatory Innovation Development Work Plan." Designated medical institutions included in the list can import and utilize urgently needed drugs and advanced medical devices already approved in Hong Kong and Macao, following regulatory approval.

This qualification enables the company to become a specialized oncology medical institution with access to innovative drugs and devices from Hong Kong and Macao. CONCORD HC GP can now introduce and utilize urgently needed oncology drugs and devices—including novel originator drugs—that are approved in Hong Kong and Macao but not yet available in mainland China. This expansion of business scope enhances the company’s differentiated competitive edge in the market while providing critical treatments to more cancer patients.

Additionally, this approval will deepen the company’s collaboration with pharmaceutical resources in Hong Kong and Macao, improving clinical diagnosis, treatment standards, and research capabilities. By introducing cutting-edge international drugs and devices, the company aims to optimize oncology treatment plans, accelerate alignment with global medical standards, and contribute to building a high-level oncology diagnosis and treatment system—ultimately enhancing patient care and therapeutic outcomes.